Published in Am J Surg Pathol on November 01, 2006
Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2. Neoplasia (2011) 1.09
Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol (2010) 1.08
Chromosomal abnormalities determined by comparative genomic hybridization are helpful in the diagnosis of atypical hepatocellular neoplasms. Histopathology (2009) 1.01
Pathobiological features of small hepatocellular carcinoma: correlation between tumor size and biological behavior. J Cancer Res Clin Oncol (2010) 1.01
Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol (2011) 1.00
Histopathology of hepatocellular carcinoma. World J Gastroenterol (2014) 0.98
Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett (2013) 0.95
Liver angiosarcoma, a rare liver malignancy, presented with intraabdominal bleeding due to rupture--a case report. World J Surg Oncol (2012) 0.94
Keratin 19 marks poor differentiation and a more aggressive behaviour in canine and human hepatocellular tumours. Comp Hepatol (2010) 0.92
Histological features of early hepatocellular carcinomas and their developmental process: for daily practical clinical application : Hepatocellular carcinoma. Hepatol Int (2008) 0.92
Early hepatocellular carcinoma: definition and diagnosis. Liver Cancer (2013) 0.91
Claudins and tricellulin in fibrolamellar hepatocellular carcinoma. Virchows Arch (2011) 0.90
Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma. Anticancer Agents Med Chem (2011) 0.89
Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol (2015) 0.85
Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. World J Gastroenterol (2012) 0.85
Expression of glypican-3 in undifferentiated embryonal sarcoma and mesenchymal hamartoma of the liver. Hum Pathol (2011) 0.82
Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis. World J Gastroenterol (2014) 0.82
Dysplastic nodules with glypican-3 positive immunostaining: a risk for early hepatocellular carcinoma. PLoS One (2014) 0.82
Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy. J Gastroenterol (2013) 0.82
Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients. Afr Health Sci (2013) 0.81
Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis. World J Hepatol (2009) 0.81
Intratumoral sampling variability in hepatocellular carcinoma: a case report. World J Gastroenterol (2007) 0.81
Hepatocellular tumors: immunohistochemical analyses for classification and prognostication. Chin J Cancer Res (2011) 0.80
Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma. J Histochem Cytochem (2013) 0.79
A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values. BMC Cancer (2013) 0.79
Proteoglycans in liver cancer. World J Gastroenterol (2016) 0.78
Maotai ameliorates diethylnitrosamine-initiated hepatocellular carcinoma formation in mice. PLoS One (2014) 0.76
Impact of PIVKA-II in diagnosis of hepatocellular carcinoma. J Adv Res (2013) 0.76
Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget (2016) 0.76
Liver-specific magnetic resonance contrast medium in the evaluation of chronic liver disease. Einstein (Sao Paulo) (2015) 0.75
Current concepts in the immunohistochemical evaluation of liver tumors. World J Hepatol (2015) 0.75
Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma. J Hepatocell Carcinoma (2014) 0.75
Seminal vesicle metastasis after partial hepatectomy for hepatocellular carcinoma. BMC Cancer (2011) 0.75
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med (2010) 8.40
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 6.14
Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell (2007) 5.91
Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med (2009) 5.26
Intrarenal resistive index after renal transplantation. N Engl J Med (2013) 4.19
Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med (2012) 3.96
Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology (2005) 3.72
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology (2014) 3.23
Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J Hepatol (2013) 2.98
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol (2012) 2.92
Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut (2010) 2.91
The onecut transcription factor HNF6 is required for normal development of the biliary tract. Development (2002) 2.89
Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol (2002) 2.65
Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology (2013) 2.64
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63
Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology (2006) 2.61
Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 2.51
Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology (2012) 2.49
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol (2007) 2.47
Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology (2008) 2.40
Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest (2011) 2.36
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33
Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol (2003) 2.27
Machine perfusion versus cold storage for preservation of kidneys from expanded criteria donors after brain death. Transpl Int (2011) 2.25
Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest (2005) 2.20
Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest (2007) 2.19
Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol (2007) 2.14
Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome. Radiology (2013) 2.12
Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut (2013) 2.10
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Minimally invasive liver surgery for metastases from colorectal cancer: oncologic outcome and prognostic factors. Surg Endosc (2012) 2.04
The β-adrenoceptor agonist isoproterenol rescues acetaminophen-injured livers through increasing progenitor numbers by Wnt in mice. Hepatology (2014) 2.03
Endoscopic resection of ampullary lesions: a single-center 8-year retrospective cohort study of 91 patients with long-term follow-up. Surg Endosc (2013) 2.01
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology (2004) 2.01
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology (2007) 1.95
The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology (2011) 1.94
Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology (2013) 1.93
Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol (2006) 1.89
Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl (2002) 1.79
Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology (2003) 1.79
Hepatic progenitor cells in human liver diseases. Semin Cell Dev Biol (2002) 1.74
A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology (2003) 1.73
Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. J Hepatol (2010) 1.70
Topography of the vanilloid receptor in the human bladder: more than just the nerve fibers. J Urol (2002) 1.69
Congenital veno-venous malformations of the liver: widely variable clinical presentations. J Gastroenterol Hepatol (2007) 1.68
Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol (2002) 1.66
Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology (2013) 1.66
Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer (2002) 1.65
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut (2012) 1.63
The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest (2005) 1.63
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol (2010) 1.61
The histology of kidney transplant failure: a long-term follow-up study. Transplantation (2014) 1.61
A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology (2005) 1.59
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol (2013) 1.57
Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology (2013) 1.57
Hepatocyte-specific IKK gamma/NEMO expression determines the degree of liver injury. Gastroenterology (2007) 1.57
Hypoxia-driven gene expression is an independent prognostic factor in stage II and III colon cancer patients. Clin Cancer Res (2014) 1.55
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol (2006) 1.54
The spectrum of nonadherence with medication in heart, liver, and lung transplant patients assessed in various ways. Transpl Int (2011) 1.53
Silencing of caspase-8 in murine hepatocellular carcinomas is mediated via methylation of an essential promoter element. Gastroenterology (2005) 1.51
Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res (2009) 1.50
Troponin I is a predictor of acute cardiac events in the immediate postoperative renal transplant period. Transplantation (2010) 1.45